Merck Belzutifan PAS

Not yet recruiting

• Conditions: Von Hippel Lindau Disease; Renal Cell Carcinoma

• Registration Number: NCT06554730
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-12
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - Greater than or equal to 18 yeas of age<br><br> - Diagnosed with VHL disease based on a germline test or clinical diagnosis<br><br> - A decision has been made by the treating physician (at his/her discrestion) to<br> intitate the first belzutifan treatment (i.e., belzutifan 'new users'), within the<br> prescribing conditions of the approved product label<br><br> - Signed informed consent prior to or withing 30 days after the first inititaion of<br> belzutifan<br><br>Exclusion Criteria:<br><br> - Anti-cancer systemic therapy within 2 weeks prior to the index date<br><br> - Unable to consent to participate in the study<br><br> - History of VHL disease-related metastasis or advanced cancer

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient Ancestry Questionnaire